Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of MG-K10 in prurigo nodularis
CTR20244735Phase 3Active
- Sponsor
- Medigene AG
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of comekibart in prurigo nodularis (PN), sponsored by Medigene AG. Started Mar 2025; status: active.
02
Drugs
comekibart
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20244735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244735.